Gyre Therapeutics (GYRE) Share-based Compensation (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Share-based Compensation for 17 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 409.47% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $9.2 million (up 232.48% YoY), while the FY2025 annual figure was $18.3 million, up 335.71% from the prior year.
• Share-based Compensation declined to $2.6 million in Q1 2026 per GYRE's latest filing, from $4.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $4.6 million in Q4 2025 and bottomed at -$1.0 million in Q4 2022.
• Historically, Share-based Compensation has averaged $726764.7 across 5 years, with a median of $237000.0 in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 250.51% — and 2025, when it soared 5562.5%.
• Gyre Therapeutics' Share-based Compensation stood at -$1.0 million in 2022, then soared by 88.33% to -$120000.0 in 2023, then soared by 1780.83% to $2.0 million in 2024, then soared by 127.91% to $4.6 million in 2025, then plunged by 43.81% to $2.6 million in 2026.
• Business Quant data shows GYRE's Share-based Compensation at $2.6 million in Q1 2026, $4.6 million in Q4 2025, and $1.1 million in Q3 2025.